Baillie Gifford & CO Bei Gene, Ltd. Call Options Transaction History
Baillie Gifford & CO
- $126 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BGNE
# of Institutions
216Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.56 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.05 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$766 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$740 Million0.59% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U03.01MShares$446 Million2.61% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $15.3B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...